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RECOMMENDATIONS
Indication of insulin treatment for patients with type 2 
diabetes mellitus
1.  Insulin therapy should be initiated if the patient fails to 
achieve the target glycemic goal despite appropriate treat-
ment with oral hypoglycemic agents [A].
2.  Insulin can be used as an initial treatment at the diagnosis of 
type 2 diabetes in the presence of metabolic decompensation 
and/or glycosylated hemoglobin >9.0% and/or symptomat-
ic hyperglycemia [E].
3.  Initiate insulin therapy in the setting of decompensated re-
nal or hepatic insufficiency, myocardial infarction, stroke, 
acute severe illness, or major surgery [B].
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Choice of type of insulin treatment
1.  A basal insulin regimen or premixed insulin injection (once 
or twice daily) should be used depending on the patient’s 
circumstances [B].
2.  If the glycemic goal is not achieved with a basal insulin or 
premixed insulin regimen, a multicomponent insulin regi-
men should be used [A].
3.  A combination therapy of oral hypoglycemic agents and insu-
lin can be employed depending on the patient’s condition [A].
WHEN SHOULD INSULIN THERAPY BE 
INITIATED?
Based on the UK Prospective Diabetes Study (UKPDS) and 
the Kumamoto study, most of the clinical practice guidelines 
for glycemic control target of type 2 diabetes mellitus (T2DM) 
since the early the 2000s have recommend the achievement of 
near-normoglycemia to prevent the onset or progression of di-
abetic microangiopathy [1,2]. The progressive nature of T2DM 
in the deterioration of pancreatic β-cell function was such that 
after 3 years, approximately 50% of patients could attain glyco-
sylated hemoglobin (HbA1c) below 7% with monotherapy, 
and by 9 years, this declined to approximately 25% [1]. Early 
intensive insulin therapy in patients with newly diagnosed 
T2DM has favorable outcomes on the recovery and mainte-
nance of β-cell function and protracted glycemic remission 
compared to treatment with oral hypoglycemic agents (OHAs) 
[3-6]; thus, supporting the rationale for the initiation of insulin 
therapy in subjects with T2DM whose glycemic targets cannot 
be achieved with lifestyle modifications and OHAs [7,8]. The 
Korean Diabetes Association recommends insulin therapy in 
two circumstances: timely initial treatment after the diagnosis 
of T2DM and in cases of OHA failure.
The initiation of insulin is recommended when severe hy-
perglycemia (more than 9% HbA1c) is detected at diagnosis, 
especially if hyperglycemic symptoms (polyuria or polydipsia) 
or any catabolic features (weight loss or ketosis) are present. 
Insulin should be also considered when adequate glycemic 
control is not obtained in patients with decompensated hepatic 
or renal insufficiency and when patients have suffered from 
myocardial infarction, stoke, or a major operation [9]. For pa-
tients with T2DM who fail to achieve the glycemic target with 
adequate treatment with OHAs, proceed to insulin injection 
therapy.
HOW TO INITIATE INSULIN THERAPY
Insulin therapy has the powerful advantage of improving the 
glycemic control better than other OHAs, but it may be associ-
ated with risks of hypoglycemia and weight gain. Therefore, 
healthcare professionals need to provide comprehensive self-
care education including insulin injection skills, self-monitor-
ing of blood glucose, hypoglycemia management, and simple 
dosage adjustment before patients begin insulin therapy [8,10].
Basal insulin alone or in combination with OHAs is easy to 
administer and is the preferred choice. Basal insulin including 
both intermediate-acting and long-acting analogue alone is the 
most convenient initial insulin regimen. Because long-acting 
basal analogues (glargine, detemir, and degludec) are evident 
for reducing the risk of hypoglycemia compared to neutral 
protamine Hagedorn (NPH) in T2DM, they are preferable to 
NPH when there is a history of hypoglycemia [11]. Recently, 
several concentrated basal insulin preparations (U-300 glargine 
and U-200 degludec) were developed to allow a higher dose of 
basal insulin injection. Premixed insulin products contain 
both a basal and prandial component (NPH/regular 70/30, 
70/30 aspart mix, 75/25, or 50/50 lispro mix), allowing cover-
age of both basal and prandial needs with a single injection. In 
the 4-T study [12,13], patients with T2DM (mean HbA1c 8.5% 
and 9-year duration of diabetes at baseline) were randomized 
to receive premixed insulin twice daily, prandial bolus insulin 
three times daily, or basal insulin once daily. In this study, me-
dian HbA1c were comparable after 3 years but weight gain and 
hypoglycemia were less with basal than with the other insulin 
regimens. In this study, however, 68% to 82% of the patients 
were taking a second type of insulin at the end of the research 
period [13]. From meta-analyses, a greater proportion of pa-
tients with T2DM achieved the HbA1c goal of <7% with bi-
phasic or prandial insulin compared to basal insulin, but these 
differences were not demonstrated after adjustment for the in-
sulin dose [14,15]. The use of premixed or prandial insulin 
compared to basal insulin was associated with more hypogly-
cemia and weight gain. Even in previously insulin-treated pa-
tients, the frequency of hypoglycemia and weight gain increas-
es as the number of insulin injections increases [15]. The con-
tribution of fasting and postprandial glucose (PPG) on overall 
hyperglycemia or HbA1c is variable among patients. PPG ex-
cursions may play a more significant role in patients with early 
mild to moderate diabetes, whereas fasting hyperglycemia 
contributes more in patients as diabetes worsens, as represent-
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ed by increasing concentrations of HbA1c, particularly at 
>8.4% [16]. When physicians initiate insulin therapy, either 
basal insulin or premixed insulin [17,18], they should under-
stand the pharmacodynamic profile of each formulation and 
also consider the baseline HbA1c in conjunction with sub-
maximal doses of sulfonylurea (SU), blood glucose levels in a 
fasting or postprandial state, and symptoms of hyperglycemia 
(polyuria or polydipsia). 
HOW TO COMBINE ORAL HYPOGLYCEMIC 
AGENTS WITH INSULIN
Insulin alone is not an ideal treatment for poorly controlled 
T2DM, as it is associated with both weight gain and inadequate 
glycemic control [19]. Various combinations of insulin with 
OHAs are now available and are widely used [20]. In patients 
with T2DM on maximum tolerated OHAs, metformin over 
placebo decreases weight gain, lowers insulin requirements, 
and improves glycemic control [19]. From meta-analyses in-
cluding 2,171 adults with uncontrolled T2DM from 11 ran-
domized controlled trials, adding insulin glargine to metfor-
min monotherapy early in treatment may provide the greatest 
24-week reductions in HbA1c and less symptomatic hypogly-
cemia benefits over regimens including SUs [21]. However, the 
Korean RCT comparing the commonly prescribed OHA com-
binations (1:1:1 basis with fixed doses of glimepiride, metfor-
min, and glimepiride plus metformin) to use as an add-on 
therapy with insulin glargine showed a significant improve-
ment in overall glycemic control with insignificant weight gain 
and the risk of hypoglycemia in the arm of combination thera-
py of metformin and glimepiride plus glargine insulin [22]. In 
this post hoc analysis of the Prospective Pioglitazone Clinical 
Trial in Macrovascular Events study (PROactive), pioglitazone 
use in combination with insulin resulted in sustained im-
proved glycemic control with a rapid and sustained decrease in 
insulin doses compared to the placebo group [23]. More insu-
lin-resistant patients (defined as poorly controlled T2DM de-
spite high doses of insulin) in the pioglitazone plus insulin 
group showed the greatest glycosylated hemoglobin decline 
[23]. From meta-analyses including 3,092 patients from eight 
RCTs comparing pioglitazone in combination with any insu-
lin-containing regimen compared to the same insulin regimen 
alone, pioglitazone confers a small advantage in terms of 
HbA1c in T2DM patients with previous inadequate glucose 
control but at the cost of increased hypoglycemia and weight 
gain [24]. Numerous studies of dipeptidyl peptidase 4 (DPP4) 
inhibitor add-on therapy compared to insulin showed signifi-
cant improvement in glycemic control relative to the placebo 
without increasing hypoglycemia or body weight [15,25,26]. 
Sodium glucose cotransporter 2 (SGLT2) inhibitor is a novel 
insulin-independent OHA that reduces hyperglycemia by re-
ducing proximal renal glucose reabsorption, causing urinary 
glucose excretion. The adjunctive use of a SGLT2 inhibitor im-
proved glycemic control and reduced weight without increas-
ing the risk of hypoglycemia and with lower insulin require-
ments, although potential side effects of urinary tract infection 
and euglycemic diabetes ketoacidosis should be considered 
[27-29]. In a covariate-adjusted indirect comparison using 
meta-regression analyses including five SGLT2 inhibitors and 
nine DPP4 inhibitors studies, SGLT2 inhibitors achieved bet-
ter glycemic control and greater weight reduction than DPP4 
inhibitors without increasing the risk of hypoglycemia in pa-
tients with T2DM that is inadequately controlled with insulin 
[30]. When physicians initiate insulin therapy in patients with 
T2DM, metformin should be continued while other oral 
agents may be continued or discontinued on an individual ba-
sis, especially insulin regimens to avoid unnecessarily complex 
or costly OHA regimens.
HOW TO INTENSIFY THE INSULIN 
THERAPY
In patients above the HbA1c target on basal insulin or pre-
mixed insulin once or twice daily, recommendations for fur-
ther intensification, if needed, are outlined in Fig. 1 [31]. When 
physicians intensify an insulin regimen, they should consider 
the advantages and disadvantages such as flexibility, complexi-
ty, and frequency of hypoglycemia. 
Intensified insulin might consist of dose titration and regi-
men modification. Once the initiation of an insulin regimen is 
stable, dose titration for adjusting insulin are made based on 
the fasting and PPG levels. If a patient is still above the HbA1c 
target with an acceptable fasting blood glucose level on titrated 
basal insulin, options for treatment intensification are either a 
single injection of rapid-acting insulin (lispro, aspart, or gluli-
sine) at the largest meal, glucagon-like peptide-1 (GLP-1) re-
ceptor agonist (GLP-1RA), or switching to twice daily injec-
tions of premixed insulin. These recommendations were based 
on the non-inferior results of basal insulin+single injection of 
either rapid-acting insulin or GLP-1RA relative to twice daily 
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premixed insulin [12,13,32-35]. Basal insulin plus GLP-1RA 
resulted in less hypoglycemia and weight loss compared to oth-
er insulin regimens [33,34]. If a patient is still above the HbA1c 
target on basal insulin+a single injection of rapid-acting insu-
lin, naturally advancing to a basal-bolus regimen (≥2 times of 
rapid-acting insulin) should be considered [36]. If a patient is 
still above the HbA1c target on initial premixed insulin once or 
twice daily with dose titration, naturally advancing to premixed 
analog insulin 2 or 3 times daily has been found to be non-infe-
rior to basal-bolus regimens with similar rates of hypoglycemia 
[17,37]. If a patient is still above the HbA1c target on an inten-
sified insulin regimen, an option for treatment is switching one 
regimen with another (such as a basal-bolus regimen to pre-
mixed analog insulin three times daily or vice versa) [38,39]. 
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Fig. 1. Treatment algorithm for insulin therapy. (A) Initiation of insulin treatment. If the initial glycosylated hemoglobin (A1C) 
level is >9.0% and symptomatic hyperglycemia or metabolic decompensation is present, insulin therapy can be initiated with or 
without oral antihyperglycemic agents (OHAs) in patients with newly diagnosed type 2 diabetes mellitus (T2DM). If the A1C tar-
get range is not achieved after implementing a basal insulin regimen, then proceed to intensification treatment, for example, addi-
tion of a glucagon-like peptide 1 receptor agonist (GLP-1RA) or a prandial insulin or switching to a premixed insulin regimen. 
(B) For adult patients with T2DM who have not achieved their glycemic target following adequate treatment using OHAs. When 
OHAs fail, proceed to basal insulin either with or without OHAs. The addition of a GLP-1RA or switching to a premixed insulin 
regimen could be another option depending on the patient’s clinical situation. The width of each black line reflects the strength of 
the expert consensus recommendations. Adapted from Ko et al. [31].
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